Company / Depreciation & Amortization
Larimar Therapeutics, Inc. Depreciation & Amortization History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$188.0K
FY2019
5-year range
$12.0K / $212.0K
FY2015-FY2019
Trend
-11.3%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $70,000 to $188,000 over the past 2 years.
Based on SEC 10-K filings.
$188,000 in FY2019 with a 5-year CAGR of +76.4%.
Increased from $70,000 to $188,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +127.3%
- 5-Year CAGR
- +76.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +76.4%, indicating consistent growth.
- In FY2019, depreciation & amortization decreased 11.3% year-over-year.
- Peak depreciation & amortization was recorded in FY2018.
- Lowest depreciation & amortization in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $188.0K | -11.3% |
| FY2018 | $212.0K | +202.9% |
| FY2017 | $70.0K | +337.5% |
| FY2016 | $16.0K | +33.3% |
| FY2015 | $12.0K | +9.1% |
| FY2014 | $11.0K | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026